February 4, 2019 10:18 AM EST

Halozyme scores $30M in cash for its latest alliance; Bernie Sanders takes aim at $375,000 rare disease drug

ENDPOINTS

→ Now it’s argenx’s turn to sign up on a collaboration deal with Halozyme aimed at using their platform tech to create subcutaneous versions of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Halozyme scores $30M in cash for its latest alliance; Bernie Sanders takes aim at $375,000 rare disease drug

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Teva launches Stelara biosimilar at 85% discount as wider field emerges

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Halozyme scores $30M in cash for its lat­est al­liance; Bernie Sanders takes aim at $375,000 rare dis­ease drug

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Halozyme scores $30M in cash for its latest alliance; Bernie Sanders takes aim at $375,000 rare disease drug